Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 8/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | DAGLB | Q8NCG7 | 2/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PTAFR | P25105 | 1/20 | 0.36 |
| ▸ | TSPO | P30536 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774478 | 0.93 | HIF1A (0.42) | MAPTSMN1; SMN2HIF1AEPAS1TBXAS1 | |
| SCHEMBL5771361 | 0.92 | NAMPT (0.42) | TBXAS1DAGLBDAGLACYP3A4PTAFR | |
| SCHEMBL5775722 | 0.91 | GSK3B (0.41) | SMN1; SMN2DAGLBDAGLAFAAHNAMPT | |
| SCHEMBL5772985 | 0.85 | GSK3B (0.41) | SMN1; SMN2FAAHNAMPT | |
| SCHEMBL5773324 | 0.84 | CYP3A4 (0.41) | MAPTTBXAS1CYP3A4PTAFRNAMPT | |
| SCHEMBL5772670 | 0.84 | POLQ (0.40) | MAPTSMN1; SMN2CYP3A4TSPO | |
| SCHEMBL5773577 | 0.83 | NAMPT (0.35) | DAGLBDAGLANAMPT | |
| SCHEMBL5776662 | 0.82 | TRPV1 (0.37) | SMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL5774056 | 0.81 | TRPV1 (0.38) | FAAH | |
| SCHEMBL5775561 | 0.80 | FAAH (0.39) | MAPTFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | MAPT 4701/4885SMN1; SMN2 3383/4885HIF1A 466/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | MAPT 4763/4885SMN1; SMN2 2449/4885HIF1A 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.